Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Intercept Pharmaceuticals, Inc.
Type
Public company
Traded as NASDAQ: ICPT
Russell 1000 Component
Industry Biotechnology
Founded 2002
Headquarters New York City, New York, United States
Key people
Mark Pruzanski
(President and CEO)
Jonathan Silverstein
(Chairman of the Board of Directors)
Website www.interceptpharma.com

Coordinates: 40°40′43″N 78°14′35″W / 40.678631°N 78.243038°W / 40.678631; -78.243038

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

The company's lead product is obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747, marketed as Ocaliva. OCA is a potent first-in-class farnesoid X receptor (FXR) agonist. As of March 2017, Ocaliva is approved in the US and the EU for use in primary biliary cholangitis. It is in phase III studies for non-alcoholic steatohepatitis (NASH) and phase II studies for primary sclerosing cholangitis.

Other products in the development pipeline include INT-767, a dual FXR/TGR5 agonist, and INT-777, a TGR5 agonist.

Intercept trades on the NASDAQ exchange under the ticker symbol ICPT. The initial public offering of the stock on October 16, 2012 was at $15. A follow-on public offering at $33 took place on June 24, 2013.

On January 9, 2014, the stock skyrocketed from $72.39 to $275.49, or about 280%, after a planned interim analysis by the independent data safety monitoring board showed that Obeticholic acid met the main goal (improvement of liver histology) at the mid-stage in the FLINT trial in NASH, sponsored by NIDDK. The stock continued to climb to $497 over the next few days before falling back to around $317 on March 29, 2014, giving a market capitalization of around $6.2 billion.

In March 2014, the company released the results of the POISE study of Obeticholic acid in PBC, which showed the drug met the trial's primary endpoint of a reduction in serum alkaline phosphatase, a biomarker for the disease. These results were presented at an international liver meeting in April 2014.

As of 31 December 2014, the company had 136 employees.

Investment goal date:
Dividends reinvested
Intercept Pharmaceuticals, Inc. ICPT report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-06
--
--
Q4 2017
2018-02-23
--
--
Q4 2017
2018-02-21
--
--
Q3 2017
2017-11-01
-2.8900
0.0000
Q2 2017
2017-07-31
-3.4600
-3.4600
Q1 2017
2017-05-04
-3.6100
-3.6100
Q4 2016
2017-02-23
-4.8400
-4.8400
Q3 2016
2016-11-03
-3.5900
-3.5900
Q2 2016
2016-08-04
-3.1400
-3.1400
Q1 2016
2016-05-05
-5.1700
-5.1700
Q4 2015
2016-02-23
-3.6200
-3.6200
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
AMERIPRISE FINANCIAL INC
2890542
BANK OF AMERICA CORP /DE/
414361
BlackRock Fund Advisors
560812
BlackRock Inc.
1069357
BlackRock Institutional Trust Company, N.A.
442854
Capital World Investors
1984959
Carmignac Gestion
2028192
CITADEL ADVISORS LLC
678553
FMR LLC
3724720
HIGHFIELDS CAPITAL MANAGEMENT LP
364232
JPMORGAN CHASE & CO
866765
ORBIMED ADVISORS LLC
1037000
STATE STREET CORP
805550
UBS Group AG
683214
Vanguard Group, Inc
1270984
Major Shareholders
Name Relationship
Total Shares
Holding stocks
ORBIMED ADVISORS LLC
5.2800% (1120609)
SILVERSTEIN JONATHAN
0.0100% (1259)
ICPT / RLYP / ROKA /
WELCH DANIEL G
0.0100% (3108)
HPTX / ICPT / ITMN / SGEN /
BRADBURY DANIEL
0.0200% (3830)
AKKARAJU SRINIVAS
0.0700% (14669)
ICPT / SGEN / VSAR / ZSPH /
SANTINI GINO
0.0200% (3927)
AMAG / HZNP / ICPT / VTAE /
SBLENDORIO GLENN
0.0200% (3729)
FOLD / ICPT / MDCO / OPHT /
VEITINGER KLAUS R DR
0.0100% (2816)
ICPT / RLYP /
Duncan Barbara Gayle
0.1500% (30808)
ICPT / MDGN / THRX /
Adorini Luciano
0.0600% (11959)
ICPT /
Genextra S.p.A.
30.4200% (6454953)
ICPT /
Fundaro Paolo
0.0500% (11498)
ICPT /
Pruzanski Mark
2.6800% (568752)
ICPT /
Shapiro David
0.2100% (44213)
ICPT /
Micheli Francesco
30.4200% (6454953)
ICPT /
Regan Daniel Paul
0.0100% (1264)
ICPT / KERX /
McMinn Rachel
0.0800% (16875)
ICPT /
Luca Benatti
0.0200% (4569)
ICPT /
Gottesdiener Keith Michael
0.0200% (3830)
ICPT /
Bright Lisa
0.1100% (22834)
ICPT /
Kapadia Sandip
0.1000% (20215)
ICPT /
Durso Jerome Benedict
0.0700% (15000)
ICPT /
Kim Richard J
0.0500% (11205)
ICPT /
% ()